Role of natural killer cells in HIV pathogenesis

Current HIV/AIDS Reports

Volumn 5, Issue 1, 2008, Pages 44-50

  Ward, Jeffrey ^a   Barker, Edward ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN RECOGNITION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL COUNT; CELL FUNCTION; CELL KILLING; CELL SUBPOPULATION; CELLULAR IMMUNITY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; REVIEW; VIREMIA;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HIV-1; HLA-B ANTIGENS; HUMANS; KILLER CELLS, NATURAL;

EID: 41649117809     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-008-0008-2     Document Type: Review

References (50)

1. Joint United Nations Programme on HIV/AIDS: Report on the Global AIDS Epidemic: Executive Summary, 2006. http://data.unaids.org/pub/GlobalReport/ 2006/2006_GR-ExecutiveSummary_en.pdf. Accessed November 5, 2007.
2. Ferlazzo G, Munz C: NK cell compartments and their activation by dendritic cells. J Immunol 2004, 172:1333-1339.
3. dim NK cells upon stimulation.
4. Moretta L, Moretta A: Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J 2004, 23:255-259.
5. Lanier LL: NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
6. Mitchell WM, Forti RL, Vogler LB, et al.: Spontaneous and interferon resistant natural killer cell anergy in AIDS. AIDS Res 1983, 1:221-229.
7. Alter G, Teigen N, Ahern R, et al.: Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007, 195:1452-1460. Demonstrates that NK cells increase in number during acute HIV infection and subside with an increase in CTL; however, with treatment disruption, NK cells and CTL increase in concert with the return of viremia.
8. Mavilio D, Benjamin J, Daucher M, et al.: Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A 2003, 100:15011-15016.
9. Portales P, Reynes J, Pinet V, et al.: Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. AIDS 2003, 17:495-504.
10. De Maria A, Fogli M, Costa P, et al.: The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003, 33:2410-2418.
11. + subset that appears with HIV infection.
12. Mela CM, Burton CT, Imami N, et al.: Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS 2005, 19:1761-1769.
13. Braud VM, Allan DS, O'Callaghan CA, et al.: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
14. Guma M, Angulo A, Vilches C, et al.: Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004, 104:3664-3671.
15. Guma M, Cabrera C, Erkizia I, et al.: Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 2006, 194:38-41.
16. Valentin A, Rosati M, Patenaude DJ, et al.: Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2002, 99:7015-7020.
17. Freud AG, Yokohama A, Beckneil B, et al.: Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006, 203:1033-1043.
18. Kottilil S, Shin K, Jackson JO, et al.: Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol 2006, 176:1107-1114.
19. Chan A, Hong DL, Atzberger A, et al.: CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007, 179:89-94.
20. Biancotto A, Grivel JC, Iglehart SJ, et al.: Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007, 109:4272-4279. Demonstration of CD4 cell decline and altered cytokine milieu in LNs of patients with HIV infection.
21. Moretta L, Ferlazzo G, Bottino C, et al.: Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006, 214:219-228.
22. Tasca S, Tambussi G, Nozza S, et al.: Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. AIDS 2003, 17:2291-2298.
23. Mavilio D, Lombardo G, Kinter A, et al.: Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med 2006, 203:2339-2350. Complete study that analyzes both DC and NK cell defects found in viremic patients. Demonstrates defective IL-10 and IL-12 secretion by and defective NK cell killing of DCs from viremic patients.
24. Flores-Villanueva PO, Yunis EJ, Delgado JC, et al.: Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A 2001, 98:5140-5145.
25. Martin MP, Gao X, Lee JH, et al.: Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429-434.
26. Carr WH, Rosen DB, Arase H, et al.: Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol 2007, 178:647-651.
27. Gillespie GM, Bashirova A, Dong T, et al.: Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes. AIDS Res Hum Retroviruses 2007, 23:451-455.
28. Thananchai H, Gillespie G, Martin MP, et al.: Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007, 178:33-37.
29. Martin MP, Qi Y, Gao X, et al.: Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39:733-740. Demonstration of increased time from seroconversion to acquisition of AIDS in individuals who possess highly expressed alleles of KIR3DL1.
30. Gaudieri S, DeSantis D, McKinnon E, et al.: Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005, 6:683-690.
31. Scott-Algara D, Truong LX, Versmisse P, et al.: Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003, 171:5663-5667.
32. Ravet S, Scott-Algara D, Bonnet E, et al.: Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007, 109:4296-4305.
33. Jennes W, Verheyden S, Demanet C, et al.: Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006, 177:6588-6592. Genetics study showing exposed, uninfected individuals have different NK cell receptor repertoires than seropositive donors.
34. Cohen GB, Gandhi RT, Davis DM, et al.: The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10:661-671.
35. Collins KL, Chen BK, Kalams SA, et al.: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998m 391:397-401.
36. Anfossi N, Andre P, Guia S, et al.: Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
37. Bonaparte MI, Barker E: Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS 2003, 17:487-494.
38. Bonaparte MI, Barker E: Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 2004, 104:2087-2094.
39. Ward JP, Bonaparte MI, Barker E: HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS 2004, 18:1769-1779.
40. Tomescu C, Chehimi J, Maino VC, Montaner LJ: NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol 2007, 179:2097-2104.
41. Ward J, Bonaparte M, Sacks J, et al.: HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 2007, 110:1207-1214. Study showing that killing of autologous in vitro HIV-infected cells by NK cells is NKG2D dependent and that HIV is able to down-regulate NTB-A and CD48.
42. Forthal DN, Landucci G, Keenan B: Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses 2001, 17:553-561.
43. Hessell AJ, Hangartner L, Hunter M, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104. Demonstrates that ADCC responses are critical during the antiviral response in a simian immunodeficiancy virus model.
44. Gupta N, Arthos J, Khazanie P, et al.: Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology 2005, 332:491-497.
45. Lucas M, Schachterle W, Oberle K, et al.: Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517.
46. Robbins SH, Bessou G, Cornillon A, et al.: Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Patbog 2007, 3:e123.
47. Goodier MR, Mela CM, Steel A, et al.: NKG2C+ NK cells are enriched in AIDS patients with advanced-stage Kaposi's sarcoma. J Virol 2007, 81:430-433.
48. Stebbing J, Gazzard B, Mandalia S, et al.: Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:2177-21783.
49. Barker E, Martinson J, Brooks C, et al.: Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS 2007, 2:2363-2365.
50. Levy JA: Prospects for an AIDS vaccine: encourage innate immunity. AIDS 2004, 18:2085-2086.